首页> 外文期刊>Cancer letters >Inhibition of growth and motility of human A549 lung carcinoma cells by a recombined vascular basement membrane derived peptide.
【24h】

Inhibition of growth and motility of human A549 lung carcinoma cells by a recombined vascular basement membrane derived peptide.

机译:重组的血管基底膜衍生肽抑制人A549肺癌细胞的生长和运动。

获取原文
获取原文并翻译 | 示例
           

摘要

We have previously constructed a recombined vascular basement membrane derived multifunctional peptide (rVBMDMP) which can inhibit tumor growth. The aim of this study is to explore the effects and mechanisms of rVBMDMP on growth and motility/invasion in human A549 lung carcinoma cells. The effect of rVBMDMP on A549 cell viability was determined by MTT assay while the motility/invasion was measured by scratch and transwell assays. Molecules that responded to rVBMDMP treatment of A549 cells were explored using the high-throughput Cancer Pathway Finder cDNA Microarray. We identified 16 genes that were up-regulated, including GZMA, ITG alphaV, MCAM and Kiss1 and 21 genes that were down-regulated, including uPA, uPAR, CDC25A, IGF1 and FGF2. Selective differentially expressed genes were further analyzed by real-time quantitative PCR and Western blot analysis. These findings contribute to the understanding of the molecular mechanisms mediating rVBMDMP action, and suggest that rVBMDMP is a promising novel agent for the treatment of human lung carcinoma.
机译:我们先前已经构建了一种重组的血管基底膜衍生多功能肽(rVBMDMP),可以抑制肿瘤的生长。这项研究的目的是探讨rVBMDMP对人A549肺癌细胞生长和运动/侵袭的影响及其机制。通过MTT测定确定rVBMDMP对A549细胞活力的影响,而通过划痕和穿孔测定测定运动性/侵袭性。使用高通量Cancer Pathway Finder cDNA微阵列研究了对rVBMDMP处理A549细胞有反应的分子。我们鉴定了16个上调的基因,包括GZMA,ITG alphaV,MCAM和Kiss1,以及21个下调的基因,包括uPA,uPA​​R,CDC25A,IGF1和FGF2。通过实时定量PCR和蛋白质印迹分析进一步分析选择性差异表达的基因。这些发现有助于对介导rVBMDMP作用的分子机制的理解,并表明rVBMDMP是用于治疗人类肺癌的有希望的新型药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号